Transmedics
TMDX

$139.88

2.36%

Market Cap: $4.66B

About: TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.

Employees: 584

Healthcare Electromedical & Electrotherapeutic Apparatus

0

Funds holding %

of 6,686 funds

0

Analysts bullish %

of 10 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

252% more first-time investments, than exits

New positions opened: 102 | Existing positions closed: 29

172% more call options, than puts

Call options by funds: $66.5M | Put options by funds: $24.5M

133% more funds holding in top 10

Funds holding in top 10: 6 [Q1] → 14 (+8) [Q2]

99% more capital invested

Capital invested by funds: $2.55B [Q1] → $5.06B (+$2.51B) [Q2]

29% more funds holding

Funds holding: 256 [Q1] → 329 (+73) [Q2]

3.46% less ownership

Funds ownership: 105.4% [Q1] → 101.94% (-3.46%) [Q2]

15% less repeat investments, than reductions

Existing positions increased: 96 | Existing positions reduced: 113

See Fund Rankings

Research analyst outlook

10 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$120

14%

downside

Avg. target

$175

25%

upside

High target

$208

49%

upside

10 analyst ratings

9 positive

90%

1 neutral

10%

0 negative

0%

Needham Mike Matson 64% 1-year accuracy 72 / 113 met price target	49%upside $208	Buy Reiterated	23 Aug 2024
Needham Mike Matson 64% 1-year accuracy 72 / 113 met price target	49%upside $208	Buy Initiated	21 Aug 2024
Stephens & Co. George Sellers 53% 1-year accuracy 9 / 17 met price target	27%upside $178	Overweight Maintained	2 Aug 2024
Piper Sandler Matt O'Brien 50% 1-year accuracy 22 / 44 met price target	29%upside $180	Overweight Maintained	1 Aug 2024
Canaccord Genuity Jason Mills 50% 1-year accuracy 2 / 4 met price target	21%upside $169	Buy Maintained	1 Aug 2024

See Analyst Rankings

Financial journalist opinion

Based on 8 articles about TMDX published over the past 30 days

The Motley Fool

Why Shares of TransMedics Stock Plunged This Week

TransMedics' one-year beta is ballooning, meaning the stock is becoming increasingly more volatile. Furthermore, a growing number of traders are betting against the stock.

Why Shares of TransMedics Stock Plunged This Week

Zacks Investment Research

TransMedics (TMDX) Is Up 3.16% in One Week: What You Should Know

Does TransMedics (TMDX) have what it takes to be a top stock pick for momentum investors? Let's find out.

TransMedics (TMDX) Is Up 3.16% in One Week: What You Should Know

Zacks Investment Research

Take the Zacks Approach to Beat the Markets: Vista Gold, TransMedics, Accenture in Focus

Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.

Take the Zacks Approach to Beat the Markets: Vista Gold, TransMedics, Accenture in Focus

TransMedics to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

ANDOVER, Mass. , Aug. 21, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that members of the management team will participate in a fireside chat at the upcoming Morgan Stanley 22nd Annual Global Healthcare Conference at the Marriott Marquis New York.

TransMedics to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

ANDOVER, Mass. , Aug. 20, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on August 16, 2024, TransMedics granted non-qualified stock options to purchase an aggregate of 3,073 shares of its common stock and an aggregate of 2,003 restricted stock units to 4 employees, each as a material inducement for each employee's entry into employment with TransMedics.

TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Zacks Investment Research

TransMedics Group, Inc. (TMDX) Hit a 52 Week High, Can the Run Continue?

TransMedics (TMDX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

TransMedics Group, Inc. (TMDX) Hit a 52 Week High, Can the Run Continue?

The Motley Fool

1 No-Brainer Growth Stock I Can't Wait to Buy Again if the Market Crashes

Recently, U.S. stock markets have been more volatile than usual. TransMedics stock has surged thanks to revenue that has more than doubled this year.

1 No-Brainer Growth Stock I Can't Wait to Buy Again if the Market Crashes

Zacks Investment Research

TransMedics (TMDX) Recently Broke Out Above the 20-Day Moving Average

TransMedics (TMDX) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, TMDX crossed above the 20-day moving average, suggesting a short-term bullish trend.

TransMedics (TMDX) Recently Broke Out Above the 20-Day Moving Average

Betting Big On TransMedics (Q2 2024 Update)

TransMedics Group, Inc. reported 117.9% YoY revenue growth in Q2 2024 and raised full-year guidance significantly, showcasing strong financial performance. Acquisition of Summit Aviation and building the largest transplant logistics network in the US enhances its competitive moat. Conservative guidance, potential for continued revenue and margin expansion, and robust management led by a visionary CEO position, position TransMedics Group for sustained growth.

Betting Big On TransMedics (Q2 2024 Update)

TransMedics: Strong Execution And Management Conservatism Is A Recipe For Success

TransMedics reported strong Q2 results, exceeding revenue and EPS estimates, and the company increased full-year guidance by $40 million at the mid-point of the new range. The company continues its beat-and-raise guidance policy, with strong performance in liver and heart transplants driving growth in the second quarter. The formation of the logistics business is increasingly looking like a great decision.

TransMedics: Strong Execution And Management Conservatism Is A Recipe For Success

See News Rankings